|Last Price$76.20||Day Change (%)-2.04%|
|Open Price$77.45||Day Change ($)-1.59|
|Day Range76.14–77.69||52-Week Range48.83–80.84|
As of Fri 4/29/2016 6:15:00 PM | USD
Robbins Arroyo LLP: Acquisition of St . Jude Medical , Inc. ( STJ ) by Abbott Laboratories (ABT) May Not Be in Shareholders' Best Interests
New Independent Data Confirms Benefits of the St . Jude Medical CardioMEMS HF System
Alere Says It Rejected Abbott Offer to Terminate Merger Deal
Alere Says It Rejected Abbott Offer to End Their Merger Deal
UPDATE: Why stock-dividend growth over next decade may be slowest since 1940s
Global Neurostimulation Devices Market Forecast to 2020 - Increasing Awareness about Mental Diseases - Research and Markets
Widening investment-grade credit spreads and rising interest rates lead to losses.
The firm is on track to meet our full-year estimates, and our $60 per share fair value estimate and wide moat rating are intact.
Each succeeding bailout entangles the global financial system even further.
There's steep price for no growth in these portfolios.